Results
1 -
10 of
20
(Click
here to explore results)
- Molecular docking and molecular dynamics studies on β-lactamases and penicillin binding proteins. K. M. Kumar, Anand Anbarasu, Sudha Ramaiah
, Mol. BioSyst.
, 2014
, 10
, 891
- Quercetin 3-O-rutinoside mediated inhibition of PBP2a: computational and experimental evidence to its anti-MRSA activity. Nidhi Rani, Saravanan Vijayakumar, Lakshmi Palanisamy Thanga Velan, Annamalai Arunachalam
, Mol. BioSyst.
, 2014
, 10
, 3229
- Recent advances in the rational design and optimization of antibacterial agents. Jesse A. Jones, Kristopher G. Virga, Giuseppe Gumina, Kirk E. Hevener
, Med. Chem. Commun.
, 2016
, 7
, 1694
- Enhanced removal of cephalosporin based antibiotics (CBA) from water by one-pot electrosynthesized Mg(OH)2: a combined theoretical and experimental study to pilot scale. Aarthi Pandiarajan, Ramakrishnan Kamaraj, Subramanyan Vasudevan
, New J. Chem.
, 2017
, 41
, 4518
- The QM/MM-QTAIM approach reveals the nature of the different reactivity of cephalosporins in the active site of L1 metallo-β-lactamase. Maria G. Khrenova, Alexandra V. Krivitskaya, Vladimir G. Tsirelson
, New J. Chem.
, 2019
, 43
, 7329
- Natural product and natural product derived drugs in clinical trials. Mark S. Butler, Avril A. B. Robertson, Matthew A. Cooper
, Nat. Prod. Rep.
, 2014
, 31
, 1612
- Natural products to drugs: natural product derived compounds in clinical trials. Mark S. Butler
, Nat. Prod. Rep.
, 2005
, 22
, 162
- Inhibitors targeting on cell wall biosynthesis pathway of MRSA. Haihong Hao, Guyue Cheng, Menghong Dai, Qinghua Wu, Zonghui Yuan
, Mol. BioSyst.
, 2012
, 8
, 2828
- Unprecedented inhibition of resistant penicillin binding
proteins by bis-2-oxoazetidinyl
macrocycles. Aline Sliwa, Georges Dive, Astrid Zervosen, Olivier Verlaine, Eric Sauvage, Jacqueline Marchand-Brynaert
, Med. Chem. Commun.
, 2012
, 3
, 344
- Natural products to drugs: natural product-derived compounds in clinical trials. Mark S. Butler
, Nat. Prod. Rep.
, 2008
, 25
, 475